AAPL325.84+0.71 (+0.22%) ▲|ABBV259.84-0.15 (-0.06%) ▼|ABT111.32+2.39 (+2.19%) ▲|ACN187.12-0.97 (-0.52%) ▼|ADBE281.61-4.47 (-1.56%) ▼|AMAT438.54-3.31 (-0.75%) ▼|AMD456.87-2.74 (-0.60%) ▼|AMGN438.17+0.05 (+0.01%) ▲|AMT172.15-3.87 (-2.20%) ▼|AMZN254.77-0.15 (-0.06%) ▼|AVGO368.52-1.17 (-0.32%) ▼|AXP329.30+5.11 (+1.58%) ▲|BA209.56+3.90 (+1.90%) ▲|BAC62.38+0.39 (+0.62%) ▲|BKNG199.29+3.60 (+1.84%) ▲|BLK1,109.93-18.18 (-1.61%) ▼|BMY67.25+0.33 (+0.49%) ▲|BNY161.23+0.72 (+0.45%) ▲|BRK-B507.84+5.51 (+1.10%) ▲|C133.51+0.97 (+0.73%) ▲|CAT784.15+4.99 (+0.64%) ▲|CL90.72+1.09 (+1.22%) ▲|CMCSA27.13+0.83 (+3.14%) ▲|COF216.74+5.40 (+2.55%) ▲|COP136.78+0.59 (+0.43%) ▲|COST930.24-9.73 (-1.03%) ▼|CRM254.45-3.66 (-1.42%) ▼|CSCO108.89-0.86 (-0.78%) ▼|CVS98.11+0.51 (+0.52%) ▲|CVX211.96+0.91 (+0.43%) ▲|DE684.61+8.53 (+1.26%) ▲|DHR209.43+2.50 (+1.21%) ▲|DIS108.66+2.44 (+2.30%) ▲|DUK120.61+0.22 (+0.18%) ▲|EMR148.52+0.89 (+0.60%) ▲|FDX321.59-3.29 (-1.01%) ▼|GD364.09-5.33 (-1.44%) ▼|GE330.34-0.75 (-0.23%) ▼|GEV916.36+17.83 (+1.98%) ▲|GILD149.43-0.50 (-0.33%) ▼|GM84.73-0.91 (-1.06%) ▼|GOOG334.51+2.48 (+0.75%) ▲|GOOGL338.17+3.15 (+0.94%) ▲|GS999.83-2.73 (-0.27%) ▼|HD319.65-0.12 (-0.04%) ▼|HON206.60-3.38 (-1.61%) ▼|IBM232.47+1.07 (+0.46%) ▲|INTC90.12+1.15 (+1.29%) ▲|INTU342.80-2.13 (-0.62%) ▼|ISRG373.18+3.93 (+1.07%) ▲|JNJ274.76+3.57 (+1.32%) ▲|JPM354.69-0.26 (-0.07%) ▼|KO88.67+0.67 (+0.76%) ▲|LIN488.49+1.73 (+0.36%) ▲|LLY1,159.72-0.28 (-0.02%) ▼|LMT531.67-12.84 (-2.36%) ▼|LOW201.42+1.37 (+0.68%) ▲|LRCX287.81-2.39 (-0.82%) ▼|MA588.52+7.42 (+1.28%) ▲|MCD261.19+0.08 (+0.03%) ▲|MDLZ62.62+1.01 (+1.63%) ▲|MDT93.35+1.31 (+1.42%) ▲|META593.20+14.66 (+2.53%) ▲|MMM169.72-0.52 (-0.31%) ▼|MO69.77+0.20 (+0.29%) ▲|MRK150.66+0.80 (+0.53%) ▲|MS211.03-0.02 (-0.01%) ▼|MSFT496.11-4.91 (-0.98%) ▼|MU945.58+12.14 (+1.30%) ▲|NEE82.80-0.13 (-0.16%) ▼|NFLX82.17+1.36 (+1.68%) ▲|NKE38.39+0.27 (+0.71%) ▲|NOW137.32-5.58 (-3.90%) ▼|NVDA224.96+7.52 (+3.46%) ▲|ORCL144.73+3.41 (+2.41%) ▲|PEP141.13+1.34 (+0.96%) ▲|PFE28.87+0.32 (+1.12%) ▲|PG147.91+1.70 (+1.16%) ▲|PLTR168.02-11.90 (-6.61%) ▼|PM188.50+1.35 (+0.72%) ▲|QCOM169.10+2.49 (+1.49%) ▲|RTX200.99-4.18 (-2.04%) ▼|SBUX107.27+1.12 (+1.06%) ▲|SCHW108.55+0.27 (+0.24%) ▲|SO88.38+0.29 (+0.33%) ▲|SPG210.22-1.65 (-0.78%) ▼|T26.29+0.29 (+1.12%) ▲|TMO604.75+4.25 (+0.71%) ▲|TMUS187.17+5.01 (+2.75%) ▲|TSLA353.08-3.02 (-0.85%) ▼|TXN255.89+2.55 (+1.01%) ▲|UBER76.82+1.58 (+2.10%) ▲|UNH398.37+2.07 (+0.52%) ▲|UNP290.17-0.45 (-0.15%) ▼|UPS103.49+0.83 (+0.80%) ▲|USB62.34+1.13 (+1.84%) ▲|V377.93+5.26 (+1.41%) ▲|VZ50.63+0.33 (+0.65%) ▲|WFC88.89+1.85 (+2.13%) ▲|WMT106.15+0.23 (+0.22%) ▲|XOM163.26-1.29 (-0.78%) ▼|AAPL325.84+0.71 (+0.22%) ▲|ABBV259.84-0.15 (-0.06%) ▼|ABT111.32+2.39 (+2.19%) ▲|ACN187.12-0.97 (-0.52%) ▼|ADBE281.61-4.47 (-1.56%) ▼|AMAT438.54-3.31 (-0.75%) ▼|AMD456.87-2.74 (-0.60%) ▼|AMGN438.17+0.05 (+0.01%) ▲|AMT172.15-3.87 (-2.20%) ▼|AMZN254.77-0.15 (-0.06%) ▼|AVGO368.52-1.17 (-0.32%) ▼|AXP329.30+5.11 (+1.58%) ▲|BA209.56+3.90 (+1.90%) ▲|BAC62.38+0.39 (+0.62%) ▲|BKNG199.29+3.60 (+1.84%) ▲|BLK1,109.93-18.18 (-1.61%) ▼|BMY67.25+0.33 (+0.49%) ▲|BNY161.23+0.72 (+0.45%) ▲|BRK-B507.84+5.51 (+1.10%) ▲|C133.51+0.97 (+0.73%) ▲|CAT784.15+4.99 (+0.64%) ▲|CL90.72+1.09 (+1.22%) ▲|CMCSA27.13+0.83 (+3.14%) ▲|COF216.74+5.40 (+2.55%) ▲|COP136.78+0.59 (+0.43%) ▲|COST930.24-9.73 (-1.03%) ▼|CRM254.45-3.66 (-1.42%) ▼|CSCO108.89-0.86 (-0.78%) ▼|CVS98.11+0.51 (+0.52%) ▲|CVX211.96+0.91 (+0.43%) ▲|DE684.61+8.53 (+1.26%) ▲|DHR209.43+2.50 (+1.21%) ▲|DIS108.66+2.44 (+2.30%) ▲|DUK120.61+0.22 (+0.18%) ▲|EMR148.52+0.89 (+0.60%) ▲|FDX321.59-3.29 (-1.01%) ▼|GD364.09-5.33 (-1.44%) ▼|GE330.34-0.75 (-0.23%) ▼|GEV916.36+17.83 (+1.98%) ▲|GILD149.43-0.50 (-0.33%) ▼|GM84.73-0.91 (-1.06%) ▼|GOOG334.51+2.48 (+0.75%) ▲|GOOGL338.17+3.15 (+0.94%) ▲|GS999.83-2.73 (-0.27%) ▼|HD319.65-0.12 (-0.04%) ▼|HON206.60-3.38 (-1.61%) ▼|IBM232.47+1.07 (+0.46%) ▲|INTC90.12+1.15 (+1.29%) ▲|INTU342.80-2.13 (-0.62%) ▼|ISRG373.18+3.93 (+1.07%) ▲|JNJ274.76+3.57 (+1.32%) ▲|JPM354.69-0.26 (-0.07%) ▼|KO88.67+0.67 (+0.76%) ▲|LIN488.49+1.73 (+0.36%) ▲|LLY1,159.72-0.28 (-0.02%) ▼|LMT531.67-12.84 (-2.36%) ▼|LOW201.42+1.37 (+0.68%) ▲|LRCX287.81-2.39 (-0.82%) ▼|MA588.52+7.42 (+1.28%) ▲|MCD261.19+0.08 (+0.03%) ▲|MDLZ62.62+1.01 (+1.63%) ▲|MDT93.35+1.31 (+1.42%) ▲|META593.20+14.66 (+2.53%) ▲|MMM169.72-0.52 (-0.31%) ▼|MO69.77+0.20 (+0.29%) ▲|MRK150.66+0.80 (+0.53%) ▲|MS211.03-0.02 (-0.01%) ▼|MSFT496.11-4.91 (-0.98%) ▼|MU945.58+12.14 (+1.30%) ▲|NEE82.80-0.13 (-0.16%) ▼|NFLX82.17+1.36 (+1.68%) ▲|NKE38.39+0.27 (+0.71%) ▲|NOW137.32-5.58 (-3.90%) ▼|NVDA224.96+7.52 (+3.46%) ▲|ORCL144.73+3.41 (+2.41%) ▲|PEP141.13+1.34 (+0.96%) ▲|PFE28.87+0.32 (+1.12%) ▲|PG147.91+1.70 (+1.16%) ▲|PLTR168.02-11.90 (-6.61%) ▼|PM188.50+1.35 (+0.72%) ▲|QCOM169.10+2.49 (+1.49%) ▲|RTX200.99-4.18 (-2.04%) ▼|SBUX107.27+1.12 (+1.06%) ▲|SCHW108.55+0.27 (+0.24%) ▲|SO88.38+0.29 (+0.33%) ▲|SPG210.22-1.65 (-0.78%) ▼|T26.29+0.29 (+1.12%) ▲|TMO604.75+4.25 (+0.71%) ▲|TMUS187.17+5.01 (+2.75%) ▲|TSLA353.08-3.02 (-0.85%) ▼|TXN255.89+2.55 (+1.01%) ▲|UBER76.82+1.58 (+2.10%) ▲|UNH398.37+2.07 (+0.52%) ▲|UNP290.17-0.45 (-0.15%) ▼|UPS103.49+0.83 (+0.80%) ▲|USB62.34+1.13 (+1.84%) ▲|V377.93+5.26 (+1.41%) ▲|VZ50.63+0.33 (+0.65%) ▲|WFC88.89+1.85 (+2.13%) ▲|WMT106.15+0.23 (+0.22%) ▲|XOM163.26-1.29 (-0.78%) ▼|
21.3 C
New York
Wednesday, September 2, 2026

Tag: property

newssourceFORcompanyinformationcontent1releasesmarket

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these.

Noble Public Adjusting Group Reports Growing Visibility Across AI-Powered Search Platforms for Large-Loss Insurance Claims

As artificial intelligence increasingly shapes consumer decision making, Noble Public Adjusting Group is being recognized as a trusted resource for policyholders navigating fire, hurricane, and large loss insurance claims.

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).

Firm Capital Property Trust Announces Completion of Competition Bureau of Canada Inquiry Regarding Acquisition of 50% Interests in Ten Manufactured Home Communities for $218...

Expected Closing Set for Q3/2026 
Expected Closing Set for Q3/2026

BiggerPockets Appoints Active Real Estate Investor Eric Augustyn as CEO, Ushering in a New Era of Platform Innovation

DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- BiggerPockets, the premier community and resource hub for real estate investors (REIs), today announced the appointment of experienced operator and active real estate investor Eric Augustyn as Chief Executive Officer.

Valens Semiconductor Appoints Karine Pinto-Flomenboim as Chief Financial Officer

HOD HASHARON, Israel, June 22, 2026 /PRNewswire/ -- Valens Semiconductor (NYSE: VLN), a leader in high-performance connectivity, today announced the appointment of Karine Pinto-Flomenboim...

ECARX Enters Definitive Agreement to Acquire Full Flyme Software Business, Securing End-to-End OS Capabilities

Full acquisition of Flyme Auto and Flyme OS secures a mature, production-proven software stack, strengthening proprietary software stack and end-to-end OS capabilities.Flyme Auto OS...

Rock Tech Lithium Expands Made-in-Ontario Lithium Supply Chain with Strategic Acquisition of Victory Project

High-grade spodumene occurrences strategically located near Trans-Canada Highway, CPKC rail, and power infrastructure adds potential feedstock opportunity for Rock Tech's Ontario mine-to-converter platform, linking...

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

Sanofi appoints Paulo Fontoura as Global Head of R&D

Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.— The Company is...

Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals

Abaxx continues to provide facts refuting ongoing misinformation, reaffirms strong business fundamentals, and confirms potential litigation.

EasySpanishTax.com Launches Simple DIY Modelo 210 Filing Solution for Non-Resident Property Owners in Spain

Founder Björn Ingbrant introduces a faster, easier and more affordable way for foreign property owners to meet their Spanish tax obligations online.MANILVA, Spain, June...

Light AI Announces Closing of C$5,000,000 Secured Convertible Debenture Unit Financing

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, June 19, 2026 /CNW/ - Light AI Inc. ("Light AI"...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new, non-executive employees.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProperty

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers